Cargando…
Chromoblastomycosis: tissue modifications during itraconazole treatment
BACKGROUND: Histological and mycological changes during itraconazole use have not been totally established in chromoblastomycosis. OBJECTIVES: To evaluate tissue modifications in chromoblastomycosis carriers under itraconazole treatment. METHODS: A histological retrospective study of 20 cases of chr...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Sociedade Brasileira de Dermatologia
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5595593/ https://www.ncbi.nlm.nih.gov/pubmed/28954095 http://dx.doi.org/10.1590/abd1806-4841.20175466 |
_version_ | 1783263391035424768 |
---|---|
author | Purim, Kátia Sheylla Malta Peretti, Murilo Calvo Fillus Neto, José Olandoski, Marcia |
author_facet | Purim, Kátia Sheylla Malta Peretti, Murilo Calvo Fillus Neto, José Olandoski, Marcia |
author_sort | Purim, Kátia Sheylla Malta |
collection | PubMed |
description | BACKGROUND: Histological and mycological changes during itraconazole use have not been totally established in chromoblastomycosis. OBJECTIVES: To evaluate tissue modifications in chromoblastomycosis carriers under itraconazole treatment. METHODS: A histological retrospective study of 20 cases of chromoblastomycosis seen at the university hospital at the south of Brazil, during itraconazole 400 mg daily treatment. Patients were classified into two groups: plaque or tumor lesions, and underwent periodic evaluations every four months during three years. Hematoxylin-eosin stain was used to analyze epidermal modifications, inflammatory infiltrate and fibrosis, and Fontana-Masson stain for parasite evaluation. RESULTS: Fontana-Masson stain was superior to hematoxylin-eosin stain in fungal count in the epidermis (mean difference=0.14; p<0.05). The most distinct mycosis tissue responses were registered in the dermis. Epidermal thinning, granulomatous infiltrate decrease or disappearance, fibrosis increase and quantitative/morphological changes occurred during treatment. STUDY LIMITATIONS: Patients could not be located to have their current skin condition examined. CONCLUSION: Parasitic and tissue changes verified in this study can reflect the parasite-host dynamics under itraconazole action. |
format | Online Article Text |
id | pubmed-5595593 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Sociedade Brasileira de Dermatologia |
record_format | MEDLINE/PubMed |
spelling | pubmed-55955932017-09-19 Chromoblastomycosis: tissue modifications during itraconazole treatment Purim, Kátia Sheylla Malta Peretti, Murilo Calvo Fillus Neto, José Olandoski, Marcia An Bras Dermatol Investigation BACKGROUND: Histological and mycological changes during itraconazole use have not been totally established in chromoblastomycosis. OBJECTIVES: To evaluate tissue modifications in chromoblastomycosis carriers under itraconazole treatment. METHODS: A histological retrospective study of 20 cases of chromoblastomycosis seen at the university hospital at the south of Brazil, during itraconazole 400 mg daily treatment. Patients were classified into two groups: plaque or tumor lesions, and underwent periodic evaluations every four months during three years. Hematoxylin-eosin stain was used to analyze epidermal modifications, inflammatory infiltrate and fibrosis, and Fontana-Masson stain for parasite evaluation. RESULTS: Fontana-Masson stain was superior to hematoxylin-eosin stain in fungal count in the epidermis (mean difference=0.14; p<0.05). The most distinct mycosis tissue responses were registered in the dermis. Epidermal thinning, granulomatous infiltrate decrease or disappearance, fibrosis increase and quantitative/morphological changes occurred during treatment. STUDY LIMITATIONS: Patients could not be located to have their current skin condition examined. CONCLUSION: Parasitic and tissue changes verified in this study can reflect the parasite-host dynamics under itraconazole action. Sociedade Brasileira de Dermatologia 2017 /pmc/articles/PMC5595593/ /pubmed/28954095 http://dx.doi.org/10.1590/abd1806-4841.20175466 Text en http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial No Derivative License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium provided the original work is properly cited and the work is not changed in any way. |
spellingShingle | Investigation Purim, Kátia Sheylla Malta Peretti, Murilo Calvo Fillus Neto, José Olandoski, Marcia Chromoblastomycosis: tissue modifications during itraconazole treatment |
title | Chromoblastomycosis: tissue modifications during itraconazole
treatment |
title_full | Chromoblastomycosis: tissue modifications during itraconazole
treatment |
title_fullStr | Chromoblastomycosis: tissue modifications during itraconazole
treatment |
title_full_unstemmed | Chromoblastomycosis: tissue modifications during itraconazole
treatment |
title_short | Chromoblastomycosis: tissue modifications during itraconazole
treatment |
title_sort | chromoblastomycosis: tissue modifications during itraconazole
treatment |
topic | Investigation |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5595593/ https://www.ncbi.nlm.nih.gov/pubmed/28954095 http://dx.doi.org/10.1590/abd1806-4841.20175466 |
work_keys_str_mv | AT purimkatiasheyllamalta chromoblastomycosistissuemodificationsduringitraconazoletreatment AT perettimurilocalvo chromoblastomycosistissuemodificationsduringitraconazoletreatment AT fillusnetojose chromoblastomycosistissuemodificationsduringitraconazoletreatment AT olandoskimarcia chromoblastomycosistissuemodificationsduringitraconazoletreatment |